U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Icon_funbox Bizarre Patents

Patent No. 6055910

/patents/6055910.html

A gun that fires a missile, powered by gas "discharged by the operator of the toy."

Newsletter  PatentStorm News

Make the Most of PatentStorm

See this month's Top Inventors and Most Cited Patents.

Stay on top of the latest patents by subscribing to an RSS feed.

Got questions? Ask a Patent Expert!

Registered users: Manage your profile, comments and alerts.

 

US Patent 6663892 - Multiple portion tablet

US Patent Issued on December 16, 2003
Estimated Patent Expiration Date: Icon_subject August 19, 2022Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
loading...


View Patent Images (PDF)
(Registered users only)

Claims



The invention claimed is:

1. A solid orally administrable pharmaceutical dosage form comprising:

a first portion containing a therapeutically effective amount of a histamine H2 -receptor antagonist; and

a second portion immediately adjacent the first portion without an intervening barrier disposed between the first portion and the second portion, the second portion containing a therapeutically effective amount of an antacid.

2. The dosage form of claim 1, wherein the histamine H2 -receptor antagonist is selected from compounds represented by the formula: ##STR2##

wherein R represents a hydrogen atom or a lower alkyl group; R1 represents an amino group, a mono- or di-lower alkyl amino group, an aryl amino group or an aralkyl amino group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group; Y represents a sulfur atom or a methylene group; m and n each represent an integer of 1-3.

3. The dosage form of claim 1, wherein the histamine H2 -receptor antagonist is selected from cimetidine, ranitidine and famotidine.

4. The dosage form of claim 1, wherein the antacid is selected from aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum aminoacetate, dihydroxy aluminum aminoacetic acid, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, hydrated magnesium aluminate, activated sulfate, magnesium aluminate, magnesium aluminosilicates, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, sodium bicarbonate and combinations of two or more of these antacids.

5. A solid orally administrable pharmaceutical dosage form comprising:


a first layer containing a therapeutically effective amount of a histamine H2 -receptor antagonist; and

a second layer immediately adjacent the first layer without an intervening barrier layer disposed between the first layer and the second layer, the second layer containing a therapeutically effective amount of an antacid.

6. The dosage form of claim 5, wherein the histamine H2 -receptor antagonist is selected from compounds represented by the formula: ##STR3##

wherein R represents a hydrogen atom or a lower alkyl group; R1 represents an amino group, a mono- or di-lower alkyl amino group, an aryl amino group or an aralkyl amino group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group; Y represents a sulfur atom or a methylene group; m and n each represent an integer of 1-3.

7. The dosage form of claim 5, wherein the histamine H2 -receptor antagonist is selected from cimetidine, ranitidine and famotidine.

8. The dosage form of claim 5, wherein the antacid is selected from aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum aminoacetate, dihydroxy aluminum aminoacetic acid, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, hydrated magnesium aluminate, activated sulfate, magnesium aluminate, magnesium aluminosilicates, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, sodium bicarbonate and combinations of two or more of these antacids.

9. The dosage form of claim 5, wherein the antacid in the second layer is selected from magnesium hydroxide, calcium carbonate, and a combination of both magnesium hydroxide and calcium carbonate.

10. The dosage form of claim 5, wherein the antacid in the second layer is selected from magnesium hydroxide, calcium carbonate, and a combination of both magnesium hydroxide and calcium carbonate, and wherein the histamine H2 -receptor antagonist is famotidine.

11. The dosage form of claim 5, further comprising a third layer containing a second antacid.

12. The dosage form of claim 11, wherein the histamine H2 -receptor antagonist is famotidine, the antacid in the second layer is one of magnesium hydroxide and calcium carbonate, and the antacid in the third layer is the other of magnesium hydroxide and calcium carbonate.

13. A process of preparing a multiple layer tablet containing a histamine H2 -receptor antagonist and an antacid, comprising:

blending a first active ingredient selected from the antacid and the histamine H2 -receptor antagonist with suitable excipients and/or adjuvants to form a first mixture;

compressing the first mixture to form a first layer of the tablet;

blending the other of the antacid and histamine H2 -receptor antagonist with excipients and/or adjuvants to form a second mixture; and

compressing the second mixture directly on the first layer to form a second layer without any intervening barrier layer between the first layer and second layer.

14. The process of claim 13, wherein the histamine H2 -receptor antagonist is selected from compounds represented by the formula: ##STR4##

wherein R represents a hydrogen atom or a lower alkyl group; R1 represents an amino group, a mono- or di-lower alkyl amino group, an aryl amino group or an aralkyl amino group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group; Y represents a sulfur atom or a methylene group; m and n each represent an integer of 1-3.

15. The process of claim 13, wherein the histamine H2 -receptor antagonist is selected from cimetidine, ranitidine and famotidine.

16. The process of claim 13, wherein the antacid is selected from aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum aminoacetate, dihydroxy aluminum aminoacetic acid, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, hydrated magnesium aluminate, activated sulfate, magnesium aluminate, magnesium aluminosilicates, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, sodium bicarbonate and combinations of two or more of these antacids.

17. The process of claim 13, wherein the antacid in the second layer is selected from magnesium hydroxide, calcium carbonate, and a combination of both magnesium hydroxide and calcium carbonate.

18. The process of claim 13, wherein the antacid in the second layer is selected from magnesium hydroxide, calcium carbonate, and a combination of both magnesium hydroxide and calcium carbonate, and wherein the histamine H2 -receptor antagonist is famotidine.

19. The process of claim 13, further comprising a third layer containing a second antacid.

20. The process of claim 19, wherein the histamine H2 -receptor antagonist is famotidine, the antacid in the second layer is one of magnesium hydroxide and calcium carbonate, and the antacid in the third layer is the other of magnesium hydroxide and calcium carbonate.

Inventor

Assignee

Application

No. 10/223127 filed on 08/19/2002

US Classes:

424/472, Layered unitary dosage forms424/464, Tablets, lozenges, or pills424/682, Aluminum, calcium or magnesium element, or compound containing424/686, Carbonate or bicarbonate424/687, Calcium carbonate424/688, Oxide or hydroxide424/689, With stabilizer or suspending agent424/690, Aluminum hydroxide424/692, Magnesium hydroxide or oxide424/715, Carbonate424/716, Ammonium carbonate424/717, Bicarbonate514/400At imidazole ring carbon

Field of Search

424/400, PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM424/464, Tablets, lozenges, or pills424/472, Layered unitary dosage forms424/682, Aluminum, calcium or magnesium element, or compound containing424/686, Carbonate or bicarbonate424/687, Calcium carbonate424/688, Oxide or hydroxide424/689, With stabilizer or suspending agent424/690, Aluminum hydroxide424/692Magnesium hydroxide or oxide

Examiners

Primary: Page, Thurman K.
Assistant: George, Konata M.

Attorney, Agent or Firm

US Patent References

701438, 2888382, 3048526, 3125491, 3358687, 3962107, Enzyme-containing denture cleanser tablet
Issued on: 06/08/1976
Inventor: Levin ,   et al.
4664915, Compressed and formed alkaline component suitable for use in buffered aspirin product
Issued on: 05/12/1987
Inventor: Simonian
4849218, Oral garlic preparations and process for preparing same
Issued on: 07/18/1989
Inventor: Hess ,   et al.
4869908, Fibre formulations
Issued on: 09/26/1989
Inventor: Kirschner ,   et al.
5085865, Sustained release pharmaceutical preparations containing an analgesic and a decongestant
Issued on: 02/04/1992
Inventor: Nayak
5190760, Solid pharmaceutical composition
Issued on: 03/02/1993
Inventor: Baker
5229137, Methods and pharmaceutical compositions for treating episodic heartburn
Issued on: 07/20/1993
Inventor: Wolfe
5571519, Organoleptically stable denture cleanser tablets
Issued on: 11/05/1996
Inventor: Synodis, et al.
5629026, Compositions containing histamine-H2-receptor antagonists at low dosage
Issued on: 05/13/1997
Inventor: Davis
5656652, Compositions containing histamine-H2 -receptor antagonists at low dosage
Issued on: 08/12/1997
Inventor: Davis
5681582, Extended release, film-coated tablet of astemizole and pseudoephedrine
Issued on: 10/28/1997
Inventor: Gilis, et al.
5736158, Partial denture cleanser with fluoride
Issued on: 04/07/1998
Inventor: Quast
5817340, Pharmaceutical compositions containing famotidine and aluminum hydroxide or magnesium hydroxide
Issued on: 10/06/1998
Inventor: Roche, et al.
6039974, Pharmaceutical composition for combination of piperidinoalkanol-decongestant
Issued on: 03/21/2000
Inventor: MacLaren, et al.
6086919, Pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
Issued on: 07/11/2000
Inventor: Bauer, et al.
6183776, Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
Issued on: 02/06/2001
Inventor: Depui, et al.
6254886, Multilayer tablet
Issued on: 07/03/2001
Inventor: Fusca, et al.
6319519Anti-inflammatory pharmaceutical formulations
Issued on: 11/20/2001
Inventor: Woolfe, et al.

International Classes

A61K 9/24 (20060101)
A61K 45/06 (20060101)
A61K 45/00 (20060101)

Comments

No comments for this page
 
 
Forgot password?
Register here